NCT00307229View on ClinicalTrials.gov

Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

May 31, 2012

Conditions
Metastatic Breast CancerRecurrent Breast Cancer
Interventions
BIOLOGICAL

adenoviral vector encoding rat Her-2/neu

Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)

Trial Locations (1)

H3T 1E2

Sir Mortimer B. Davis - Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

Ontario Cancer Research Network

NETWORK

collaborator

Canadian Breast Cancer Research Alliance

OTHER

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00307229 - Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) | Biotech Hunter | Biotech Hunter